Navigate Fool.com
Will BIIB beat
the market?

Biogen Idec (NASDAQ: BIIB)

Community Rating: 4 Stars: Favorite

336.78 -0.82 (-0.24%)

REAL-TIME: Last trade at

Extended Hours: $336.79 $0.15 (0.04%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $337.60
Previous Close $337.60
Daily Range $335.22 - $339.83
52-Week Range $203.55 - $358.89
Market Cap $79.9B
P/E Ratio 37.55
Dividend (Yield) $0.00 (0.0%)
Volume 1,519,089
Average Daily Volume 1,199,549
Current FY EPS $11.28

How do you think BIIB
will perform against the market?

Top BIIB Bull/Bear Pitches


sugarmag23 (0)
Submitted June 5, 2013

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

0 Replies Reply Report this Post

NetscribeBiotech (< 20)
Submitted February 19, 2007

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, A … More

4 Replies Reply Report this Post

News & Commentary Rss Feed

Why Biogen Idec Stock Is Firing on All Cylinders

Biogen Idec's latest earnings report is the envy of the industry with better than expected growth of its soon to be best-seller Tecfidera.

IYH, PFE, ABBV, BIIB: Large Outflows Detected at ETF

U.S. stocks: Futures up as Ford, Facebook rise premarket

3 Key Takeaways from Biogen Idec Inc Stock's Earnings Annihilation

An executive summary of a monster quarter

Biogen Stock's Tecfidera Embarrasses Wall Street

Sales of Biogen's (BIIB) MS drug Tecfidera soared again last quarter as it won market share away from competing oral MS drugs from Novartis (NVS) and Sanofi (SNY).

Closing Update: Blue Chips Decline But Broader Indices Extend Gains On Mostly Positive Earnings Resu

Closing Update: Blue Chips Decline But Broader Indices Extend Gains On Mostly Positive Earnings Results

Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target

Why Biogen Idec Inc. Stock Popped Today

Is this meaningful? Or just another movement?

5 Novartis Drugs You Need To Know About

Biogen (BIIB) and Regeneron (REGN) pose threats to Novartis' (NVS) sales as Diovan competitors launch.

Stocks start mixed as tensions ease

See More BIIB News...





Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website: http://www.biogenidec.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks